MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
ConclusionThe activity and safety of first-line FOLFIRI/aflibercept merit further evaluation in randomized studies.Clinicaltrials.gov registration numberNCT02624726. (Source: Targeted Oncology)
Source: Targeted Oncology - June 15, 2019 Category: Cancer & Oncology Source Type: research

Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases
ConclusionsTheEGFR T790M mutation in plasma cfDNA is a sensitive marker for EGFR TKI resistance when CNS metastases progressed. CSF ctDNA increases the diagnostic validity forEGFR genotyping of lung cancer brain metastasis. ddPCR in CSF and plasma samples could provide less invasive and close monitoring of theEGFR status of LAC patients with CNS metastases. (Source: Targeted Oncology)
Source: Targeted Oncology - June 3, 2019 Category: Cancer & Oncology Source Type: research

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
ConclusionsChemotherapy could be an effective option after osimertinib failure in unselected patients. (Source: Targeted Oncology)
Source: Targeted Oncology - May 23, 2019 Category: Cancer & Oncology Source Type: research

Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer
ConclusionThe efficacy of osimertinib as second-line treatment or more in octogenarian pretreated patients with EGFR T790M-mutated advanced NSCLC in a real-life setting was similar to that in randomized controlled trials. (Source: Targeted Oncology)
Source: Targeted Oncology - May 22, 2019 Category: Cancer & Oncology Source Type: research

Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo
ConclusionsVosaroxin and venetoclax synergistically induce apoptosis in acute myeloid leukemia cells and cooperatively target acute myeloid leukemia progenitor cells while sparing normal hematopoietic progenitor cells. Our results support the clinical testing of vosaroxin in combination with venetoclax for treating patients with acute myeloid leukemia, especially in the elderly population. (Source: Targeted Oncology)
Source: Targeted Oncology - May 21, 2019 Category: Cancer & Oncology Source Type: research

Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
ConclusionsNo significant difference was observed for OS between the standard group and the reduced group. However, there were fewer adverse events in the reduced group. The optimal initial dose of regorafenib should be identified in further studies. (Source: Targeted Oncology)
Source: Targeted Oncology - May 15, 2019 Category: Cancer & Oncology Source Type: research

The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes
AbstractSeveral urinary disorders, including overactive bladder, urinary incontinence, and interstitial cystitis, are often characterized by negative urine cultures. The application of metagenomics (i.e., 16S rRNA microbial profiling or whole-genome shotgun sequencing) to urine samples has enabled the identification of previously undetected bacteria, contributing to the discovery and characterization of the urinary microbiome. The most frequent species isolated areLactobacillus (15%),Corynebacterium (14.2%),Streptococcus (11.9%),Actinomyces (6.9%), andStaphylococcus (6.9%). Although several studies are emerging in this con...
Source: Targeted Oncology - May 9, 2019 Category: Cancer & Oncology Source Type: research

Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies
AbstractDevelopments in systemic therapies beyond traditional cytotoxic chemotherapy have resulted in an unparalleled number of US Food and Drug Administration approvals in the past 5  years for ovarian, endometrial, and cervical cancer. In this review, we highlight registration trials leading to recent Food and Drug Administration approvals for targeted systemic therapies in advanced gynecologic malignancies, encompassing three classes of agents: the antiangiogenic anti-vascula r endothelial growth factor antibody bevacizumab in ovarian and cervical cancer, poly (ADP-ribose) polymerase inhibitors in ovarian cancer, a...
Source: Targeted Oncology - May 8, 2019 Category: Cancer & Oncology Source Type: research

Efficacy of Crizotinib for Advanced ALK -Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China
ConclusionsALK-rearranged advanced NSCLC patients with baseline brain metastasis can still achieve OS benefits from crizotinib treatment. However, patients with intracranial progression may not obtain a  long-term survival benefit from continuation of CBPD. (Source: Targeted Oncology)
Source: Targeted Oncology - April 25, 2019 Category: Cancer & Oncology Source Type: research

Comment on: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”
(Source: Targeted Oncology)
Source: Targeted Oncology - April 24, 2019 Category: Cancer & Oncology Source Type: research

Authors ’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”
(Source: Targeted Oncology)
Source: Targeted Oncology - April 24, 2019 Category: Cancer & Oncology Source Type: research

Crizotinib in Chinese Patients with ROS1 -Rearranged Advanced Non ‒Small-Cell Lung Cancer in Routine Clinical Practice
ConclusionCrizotinib was effective and well tolerated in Chinese patients withROS1-positive advanced NSCLC in real-world clinical practice. The progression sites and patterns, as well as treatments after first disease progression on crizotinib were diverse. Crizotinib beyond progressive disease and local therapy after failure of crizotinib treatment were feasible and effective in clinical practice. (Source: Targeted Oncology)
Source: Targeted Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis
ConclusionsWithin the limitations of this network meta-analysis, the comparison indicates that CDK4/6is plus AIs might represent a better option for HR+  ABC as a first-line endocrine treatment compared with fulvestrant. (Source: Targeted Oncology)
Source: Targeted Oncology - April 3, 2019 Category: Cancer & Oncology Source Type: research

Inhibiting Bruton ’s Tyrosine Kinase in CLL and Other B-Cell Malignancies
AbstractInhibitors of Bruton ’s tyrosine kinase (BTK), a major kinase in the B-cell receptor (BCR) signaling pathway, mediating B-cell proliferation and apoptosis, have substantially altered the management, clinical course, and outcome of patients with B-cell malignancies. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Newer and more selective BTK inhibitors are currently ...
Source: Targeted Oncology - March 30, 2019 Category: Cancer & Oncology Source Type: research

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
ConclusionsThis parallel approach through contemporary post-marketing analysis and OoSRs confirmed that ICIs are associated with a multitude of irAEs, with different reporting patterns between anti-CTLA4 and anti-PD1/PDL1 medications. Close clinical monitoring is warranted to early diagnose and timely manage irAEs, especially respiratory, endocrine, and hepatic toxicities, which warrant further characterization; patient- and drug-related risk factors should be assessed through analytical pharmaco-epidemiological studies and prospective multicenter registries. (Source: Targeted Oncology)
Source: Targeted Oncology - March 29, 2019 Category: Cancer & Oncology Source Type: research

Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
AbstractBackgroundPatients in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate-risk group have heterogeneous prognoses and thus may benefit from improved risk stratification.ObjectiveThe aim of this study was to analyze inflammatory parameters such as C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic markers for IMDC intermediate-risk patients.MethodsPatients with metastatic clear cell renal cell carcinoma (n  =  71) with IMDC intermediate risk who received tyrosine kinase inhibitors as first-line therapy were included in this retrospectiv...
Source: Targeted Oncology - March 29, 2019 Category: Cancer & Oncology Source Type: research

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
AbstractBackgroundPeripheral T-cell lymphoma (PTCL) is associated with poor prognosis, particularly in patients with relapsed/refractory (R/R) disease. Pralatrexate, a folate analogue inhibitor, was the first drug approved to treat R/R PTCL.ObjectiveAs the distribution of PTCL subtypes differs between populations and few patients in the pivotal trial of pralatrexate were Asian, this study investigated the safety and efficacy of pralatrexate as monotherapy in Chinese patients with R/R PTCL.Patients and MethodsIn this single-arm, open-label, multicenter study, 71 patients with R/R PTCL (median [range] 2 [1 –14] prior s...
Source: Targeted Oncology - March 23, 2019 Category: Cancer & Oncology Source Type: research

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib
ConclusionsThis study illustrates the patterns ofALK fusion variants present in Chinese NSCLC patients and might help explain heterogeneous clinical outcomes to crizotinib treatment according to differentALK fusion variants. (Source: Targeted Oncology)
Source: Targeted Oncology - March 20, 2019 Category: Cancer & Oncology Source Type: research

Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
ConclusionsBoth first-generation EGFR  TKIs and the ALK TKI crizotinib were effective in these patients. Sequential treatment with EGFR TKIs and crizotinib should be considered as a management option. (Source: Targeted Oncology)
Source: Targeted Oncology - March 19, 2019 Category: Cancer & Oncology Source Type: research

Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
AbstractBackgroundSerum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role in patients with cancer, particularly those treated with targeted agents, is unknown.ObjectiveWe conducted this study to explore the prognostic value of SPF in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors and its association with clinical characteristics.MethodsPatients with mRCC (n = 213) who initiated first-line sunitinib or sorafenib systemic therapy for metastatic disease between March 2007 and June 2017...
Source: Targeted Oncology - March 18, 2019 Category: Cancer & Oncology Source Type: research

Rucaparib: A Review in Ovarian Cancer
AbstractRucaparib (Rubraca®) is a small molecule poly(ADP-ribose) polymerase (PARP) inhibitor with potent activity against PARP-1, -2 and -3. It is approved in the USA and the EU for the treatment of adult patients withBRCA-mutated ovarian cancer who have been treated with two or more lines of chemotherapy. Rucaparib is also approved in the USA and the EU for use as maintenance therapy in adult patients with recurrent or relapsed ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Based on an analysis of patients across two phase  II clinical trials, rucaparib displayed clinica...
Source: Targeted Oncology - March 4, 2019 Category: Cancer & Oncology Source Type: research

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR
ConclusionsWe observed a high concordance between ddPCR and Cobas in detectingEGFR mutations in plasma samples of patients with advancedEGFR-mutated lung adenocarcinoma, but ddPCR was more sensitive than Cobas. (Source: Targeted Oncology)
Source: Targeted Oncology - February 27, 2019 Category: Cancer & Oncology Source Type: research

Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models
ConclusionsOur findings provide insight into the molecular mechanism of resistance to afatinib and support further clinical evaluation into the combination of afatinib and MEK inhibition in the treatment of oral squamous cell carcinoma. (Source: Targeted Oncology)
Source: Targeted Oncology - February 26, 2019 Category: Cancer & Oncology Source Type: research

The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies
AbstractHepatocellular carcinoma (HCC) is one of the most common and deadliest cancers worldwide with a rising incidence in the Western world. HCCs are characterized by high resistance to systemic therapies induced by phenotypic and molecular heterogeneity. For almost 10  years, the tyrosine kinase inhibitor sorafenib was the only approved treatment for advanced HCCs in patients with preserved liver function, and until 2016, no new compounds tested in large phase III studies have led to a survival benefit. The tyrosine kinase inhibitor regorafenib, a fluorinated so rafenib analog, was the first substance that showed a...
Source: Targeted Oncology - February 25, 2019 Category: Cancer & Oncology Source Type: research

Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
AbstractCabozantinib is an inhibitor of multiple receptor tyrosine kinases (RTKs) with roles in cancer pathogenesis. This review focuses on data relevant to the use of cabozantinib tablets (Cabometyx®) in the treatment of hepatocellular carcinoma (HCC) in patients who have been previously treated with the multi-RTK inhibitor sorafenib, an indication for which cabozantinib tablets are approved in the EU and USA. Approval of cabozantinib in this setting was based largely on the findings of CELESTIAL, a phase 3 trial in adults with advanced HCC who had previously received sorafenib, had progressive disease after at least ...
Source: Targeted Oncology - February 14, 2019 Category: Cancer & Oncology Source Type: research

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
ConclusionsBI 853520 has a manageable and acceptable safety profile, favorable PK, and modest antitumor activity at an MTD of 200  mg QD in patients with selected advanced nonhematologic malignancies.ClinicalTrials.gov identifierNCT01335269. (Source: Targeted Oncology)
Source: Targeted Oncology - February 11, 2019 Category: Cancer & Oncology Source Type: research

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI  853520
ConclusionsThese studies demonstrate that BI  853520 can be given with no food restrictions, and as a liquid dispersion, without strongly impacting pharmacokinetics. These pharmacokinetic properties may help make BI 853520 dosing more convenient and flexible, improving treatment compliance.Clinical trials registrationClinicalTrials.gov identifier: NCT01335269. (Source: Targeted Oncology)
Source: Targeted Oncology - February 11, 2019 Category: Cancer & Oncology Source Type: research

Phase I Study of the Focal Adhesion Kinase Inhibitor BI  853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
ConclusionsThis trial demonstrated a manageable and acceptable safety profile, favorable pharmacokinetics, and potential anti-tumor activity of BI  853520 in pretreated Japanese and Taiwanese patients with advanced or metastatic solid tumors.Clinical trials registrationNCT01905111. (Source: Targeted Oncology)
Source: Targeted Oncology - February 6, 2019 Category: Cancer & Oncology Source Type: research

BI 853520, a FAK-Simile of Prior FAK Inhibitors?
(Source: Targeted Oncology)
Source: Targeted Oncology - February 1, 2019 Category: Cancer & Oncology Source Type: research

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
AbstractBladder cancer is the fourth most common cancer in men and the ninth most common in women in the Western world. The management of bladder carcinoma requires a multidisciplinary approach. Optimal treatment depends on several factors, including histology, stage, patient status, and possible comorbidities. Here we review recent findings on the treatment of muscle-invasive bladder carcinoma, advanced urothelial carcinoma, upper tract urothelial carcinoma, non-urothelial carcinoma, and urologic complications arising from the disease or treatment. In addition, we present the recommendations of the Spanish Oncology Genito...
Source: Targeted Oncology - January 29, 2019 Category: Cancer & Oncology Source Type: research

Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry
AbstractBackgroundMicrosatellite instability (MSI) is the molecular marker for DNA mismatch repair deficiency (dMMR) in colorectal cancer (CRC) and has been associated with better survival outcomes in early stage disease. In metastatic CRC (mCRC), outcomes for patients with MSI are less clear. There is evolving evidence that treatment pathways for MSI CRC should include programmed-death 1 (PD-1) antibodies.ObjectiveAn analysis was performed to explore the impact of MSI status on overall survival (OS) in mCRC.Patients and methodsSouth Australian Metastatic CRC Registry data were analysed to assess patient characteristics an...
Source: Targeted Oncology - January 18, 2019 Category: Cancer & Oncology Source Type: research

Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
ConclusionA novel EGFR-targeting ADC, RC68-PY-VC-PAB-MMAE, shows promise as an effective, selective, and safe therapeutic agent for EGFR-positive pancreatic cancer. (Source: Targeted Oncology)
Source: Targeted Oncology - January 11, 2019 Category: Cancer & Oncology Source Type: research

Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
ConclusionsThe encouraging PFS and favorable safety profile observed in the FavorAx study support the administration of axitinib in mRCC patients with favorable IMDC risk and a history of prior sunitinib or pazopanib. (Source: Targeted Oncology)
Source: Targeted Oncology - January 3, 2019 Category: Cancer & Oncology Source Type: research

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
ConclusionEGFR T790M mutation is a major mechanism of acquired resistance to afatinib. Osimertinib confers high response rates after afatinib failure inEGFR T790M-positive patients and its use in sequence potentially allows extended chemotherapy-free treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - December 12, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
The article Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer, written by Sarah Sammons, Noah S. Kornblum and Kimberly L. Blackwell, was originally published electronically on the publisher ’s internet portal (currently SpringerLink). (Source: Targeted Oncology)
Source: Targeted Oncology - December 8, 2018 Category: Cancer & Oncology Source Type: research

Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment
This article summarizes the key clinical trials that led to FDA approval of ARAT in the mHSPC and nmCRPC settings and highlights potential limitations, future directions, and treatment-algorithms when selecting patients for early therapy in mHSPC and NMPC. (Source: Targeted Oncology)
Source: Targeted Oncology - December 7, 2018 Category: Cancer & Oncology Source Type: research

PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer
ConclusionsPD-1 seems to be less often expressed in male breast cancer compared to female breast cancer. Although PD-1 and PD-L1 are not definite indicators for good or bad responses, male breast cancer patients may therefore respond differently to checkpoint immunotherapy with PD-1 inhibitors than female patients. (Source: Targeted Oncology)
Source: Targeted Oncology - December 5, 2018 Category: Cancer & Oncology Source Type: research

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
ConclusionsCombination of G and T is feasible in patients with locally advanced or MPC with manageable side effects, but lacks clinical efficacy.The study was registered in the Australian New Zealand Clinical Trials Registry (ACTRN12611000643976). (Source: Targeted Oncology)
Source: Targeted Oncology - November 28, 2018 Category: Cancer & Oncology Source Type: research

New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer
AbstractOnly a limited number of therapeutic strategies are available for patients diagnosed with pancreatic adenocarcinoma, and disease recurrence and mortality are consequently high. For metastatic disease, two combinations are approved in the first line setting: a triplet with 5-fluoruracil, irinotecan, and oxaliplatin, and the combination of gemcitabine and nab-paclitaxel. In patients who have progressed on gemcitabine, a new nanoliposomal formulation of irinotecan has recently been approved. While these treatments have demonstrated some efficacy, there has been little increase in survival rates for metastatic pancreat...
Source: Targeted Oncology - November 23, 2018 Category: Cancer & Oncology Source Type: research

Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy
AbstractOlaparib (Lynparza ®), a first-in-class poly (ADP-ribose) polymerase (PARP) inhibitor, has recently been approved in a new tablet formulation as maintenance treatment for recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platin um-based chemotherapy. Relative to an earlier capsule formulation, the tablet formulation of olaparib has improved bioavailability, thereby reducing pill burden and offering a more convenient dosage regimen. In the phase III SOLO2 study, maintenance treatment with olaparib tablets significantly pro...
Source: Targeted Oncology - November 20, 2018 Category: Cancer & Oncology Source Type: research

Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
ConclusionsTo our knowledge, this is the first population-based study of olaparib real-world use and outcomes. During the first three years following regulatory approval, olaparib was mainly prescribed to ovarian cancer patients. Ovarian cancer patients stayed on olaparib for a median of 9.5  months and the treatment appeared to be well tolerated. (Source: Targeted Oncology)
Source: Targeted Oncology - November 16, 2018 Category: Cancer & Oncology Source Type: research

Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib
ConclusionsOur data provide pre-clinical information that can be incorporated into future early-phase clinical trials for the assessment of carfilzomib as a treatment for children with refractory hematological malignancies. (Source: Targeted Oncology)
Source: Targeted Oncology - November 16, 2018 Category: Cancer & Oncology Source Type: research

Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - November 13, 2018 Category: Cancer & Oncology Source Type: research

Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19 –23 October 2018
(Source: Targeted Oncology)
Source: Targeted Oncology - November 13, 2018 Category: Cancer & Oncology Source Type: research

Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
AbstractBackgroundStromal tumor-infiltrating lymphocytes (sTILs) have been identified as a predictive biomarker for response to neoadjuvant chemotherapy (NAC) and prognosis in human epidermal growth factor receptor 2 (HER2)-positive breast cancers. However, standardized scoring methods for use in clinical practice need to be established, and the optimal threshold of sTILs to predict pathological complete response (pCR) and prognosis in HER2+ breast cancers has not yet been defined.ObjectiveThe predictive and prognostic values of sTILs in patients with HER2-positive breast cancer treated with NAC were evaluated, with the ai...
Source: Targeted Oncology - November 7, 2018 Category: Cancer & Oncology Source Type: research

Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
ConclusionsDelayed addition of anti-EGFR mAbs to first-line chemotherapy was not associated with inferior survival or response rates. (Source: Targeted Oncology)
Source: Targeted Oncology - October 23, 2018 Category: Cancer & Oncology Source Type: research

Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma
AbstractBackgroundSarcopenia is a state of degenerative skeletal muscle wasting induced by cancer cachexia.ObjectiveTo evaluate the prognostic impact of changes in skeletal muscle mass (SMM) during first-line sunitinib therapy on oncological outcomes in metastatic renal cell carcinoma (mRCC).Patients and MethodsSixty-nine patients were evaluated retrospectively. The skeletal muscle index (SMI) was calculated based on computed tomography images obtained before the initiation (pre-treatment SMI) and after two cycles of sunitinib treatment (post-treatment SMI). The change in SMM was evaluated based on the value of ΔSMI,...
Source: Targeted Oncology - October 16, 2018 Category: Cancer & Oncology Source Type: research

Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy
ConclusionCytoreductive nephrectomy seems to result in a survival benefit in both clear cell and non-clear cell histology, while no survival advantage was found in patients with specific clinical features. Despite a high level of heterogeneity, our results highlight the importance of a good selection of patients to whom a primary surgical approach could be proposed. (Source: Targeted Oncology)
Source: Targeted Oncology - October 15, 2018 Category: Cancer & Oncology Source Type: research

Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy
AbstractBackgroundA consistent percentage of patients with metastatic non-small cell lung cancer (NSCLC) derives no or only marginal benefit from immunotherapy (IO).ObjectiveSince serum sodium has been linked to both prognosis in NSCLC and modulation of immune cells activity, we aimed to assess the association between low baseline serum sodium concentration ( ≤ 135 mEq/L) and clinical outcomes of patients with metastatic NSCLC treated with IO.Patients and MethodsWe included metastatic NSCLC patients treated with checkpoint inhibitors in our department from April 2013 to April 2018 with available baseline serum sodi...
Source: Targeted Oncology - October 10, 2018 Category: Cancer & Oncology Source Type: research

EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
AbstractBackgroundNon-small cell lung cancer (NSCLC) has a 5-year survival of 5 –16%. Epidermal growth factor receptor (EGFR) mutations, in most cases, confer sensitivity toEGFR tyrosine kinase inhibitor (TKI) therapy. Nonetheless, it is still unclear why clinical outcomes vary among patients with identicalEGFR mutations. The amplification of theEGFR gene (EGFRamp) may play a significant role.ObjectiveCompare the complete (CR) and partial response (PR) rates, overall survival (OS), and progression-free survival (PFS) in Hispanic patients with lung adenocarcinoma treated with erlotinib withEGFR mutations (L858R or exo...
Source: Targeted Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research